AZN.UK

11,400

+2.24%↑

HLN.UK

392.8

+1.34%↑

INDV

742.5

+1.64%↑

AZN.UK

11,400

+2.24%↑

HLN.UK

392.8

+1.34%↑

INDV

742.5

+1.64%↑

AZN.UK

11,400

+2.24%↑

HLN.UK

392.8

+1.34%↑

INDV

742.5

+1.64%↑

AZN.UK

11,400

+2.24%↑

HLN.UK

392.8

+1.34%↑

INDV

742.5

+1.64%↑

AZN.UK

11,400

+2.24%↑

HLN.UK

392.8

+1.34%↑

INDV

742.5

+1.64%↑

Search

GlaxoSmithKline PLC

Open

SectorHealthcare

1,456 2.5

Overview

Share price change

24h

Current

Min

1415.5

Max

1462.5

Key metrics

By Trading Economics

Income

559M

501M

Sales

105M

8.1B

P/E

Sector Avg

23.581

63.778

EPS

0.232

Dividend yield

4.3

Profit margin

6.172

Employees

68,629

EBITDA

-52M

1.1B

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+8.46% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

4.30%

2.39%

Next Earnings

30 kwi 2025

Next Dividend date

10 kwi 2025

Next Ex Dividend date

15 maj 2025

Market Stats

By TradingEconomics

Market Cap

-586M

59B

Previous open

1453.5

Previous close

1456

News Sentiment

By Acuity

38%

62%

139 / 386 Ranking in Healthcare

GlaxoSmithKline PLC Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

5 lut 2025, 11:32 UTC

Earnings

GSK Launches $2.5 Billion Buyback, Raises Midterm Sales Outlook -- 2nd Update

5 lut 2025, 08:56 UTC

Earnings

Correction to GSK Article

5 lut 2025, 08:24 UTC

Earnings

GSK Issues $2.5 Billion Buyback, Raises Midterm Outlook After Beating Market Views -- Update

5 lut 2025, 07:43 UTC

Earnings

GSK Expects Further Profit Growth After Beating Market Views

13 sty 2025, 07:14 UTC

Acquisitions, Mergers, Takeovers

GSK to Buy U.S. Rare Tumor Specialist IDRx for Up to $1.15 Billion

2 kwi 2025, 09:27 UTC

Hot Stocks

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

26 mar 2025, 22:29 UTC

Top News

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- 2nd Update

26 mar 2025, 19:19 UTC

Top News

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- Update

26 mar 2025, 17:39 UTC

Top News

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- WSJ

19 mar 2025, 14:50 UTC

Top News

HIV Drug Makers Get Spooked by Trump Cuts, but Impact Looks Manageable -- Heard on the Street -- WSJ

17 mar 2025, 09:00 UTC

Top News

Pfizer Has a New Playbook for Reviving Sales -- And It's Starting to Pay Off -- WSJ

24 lut 2025, 07:05 UTC

Acquisitions, Mergers, Takeovers

GSK Completes Acquisition of IDRx

14 lut 2025, 11:38 UTC

Top News
Earnings

Moderna's Results Reaffirm a Grim Picture for Vaccine Maker -- Barrons.com

14 lut 2025, 11:30 UTC

Top News
Earnings

Moderna's Results Reaffirm a Grim Picture for Vaccine Maker -- Barrons.com

5 lut 2025, 15:33 UTC

Market Talk
Earnings

GSK's Pipeline Has to Prove It Can Counter Concerns Over Vaccine Business -- Market Talk

5 lut 2025, 08:38 UTC

Market Talk
Earnings

GSK Needs to Show It Can Navigate Vaccines Challenge -- Market Talk

5 lut 2025, 07:05 UTC

Earnings

GSK PLC Had Seen 2031 Sales Outlook at More Than GBP38B

5 lut 2025, 07:04 UTC

Earnings

GSK PLC Sees 2031 Sales Outlook at More Than GBP40B

5 lut 2025, 07:03 UTC

Earnings

GSK PLC Sees 2025 Adjusted EPS Growth of 6%-8%

5 lut 2025, 07:03 UTC

Earnings

GSK PLC Raises Mid-Term View

5 lut 2025, 07:03 UTC

Earnings

GSK PLC Sees 2025 Adjusted Operating Growth of 6% - 8%

5 lut 2025, 07:02 UTC

Earnings

GSK PLC Sees 2025 Turnover Growth of 3% to 5%

5 lut 2025, 07:02 UTC

Earnings

GSK PLC Issues GBP2B Buyback

5 lut 2025, 07:01 UTC

Earnings

GSK PLC Declares 4Q Dividend of 16p

5 lut 2025, 07:00 UTC

Earnings

GSK PLC 4Q Core EPS Consensus Was 20.6p

5 lut 2025, 07:00 UTC

Earnings

GSK PLC 4Q Sales Consensus Was GBP7.83B

5 lut 2025, 07:00 UTC

Earnings

GSK PLC 4Q Pretax Pft GBP563M

5 lut 2025, 07:00 UTC

Earnings

GSK PLC 4Q EPS 10.0p

5 lut 2025, 07:00 UTC

Earnings

GSK PLC 4Q Adj EPS 23.2p

5 lut 2025, 07:00 UTC

Earnings

GSK PLC 4Q Oper Pft GBP696M

Peer Comparison

Price change

GlaxoSmithKline PLC Forecast

Price Target

By TipRanks

8.46% upside

12 Months Forecast

Average 1,593.33 GBX  8.46%

High 2,290 GBX

Low 1,450 GBX

Based on 12 Wall Street analysts offering 12 month price targets forGlaxoSmithKline PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

12 ratings

2

Buy

8

Hold

2

Sell

Sentiment

By Acuity

139 / 386 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.